Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial

Abstract

BackgroundProbiotics have rarely been studied in young healthy infants from low-income countries. This phase I study investigated the safety and acceptability of two probiotics in Bangladesh.MethodsHealthy infants aged four to twelve weeks from urban slums in Bangladesh were randomized to one of three different intervention dosing arms (daily, weekly, biweekly – once every two weeks) of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 over one month or to a fourth arm that received no probiotics. All subjects were followed for two additional months. Reported gastrointestinal and respiratory symptoms as well as breastfeeding rates, hospitalizations, differential withdrawals, and caretakers’ perception of probiotic use were compared among arms.ResultsIn total, 160 infants were randomized (40 to each arm) with 137 (Daily n = 35, Weekly n = 35, Biweekly n = 35, Control n = 32) followed up for a median of twelve weeks; 113 completed the study. Illness and breastfeeding rates were similar across all arms. Ten hospitalizations unrelated to probiotic use occurred. Forty eight percent of the caretakers of infants in intervention arms believed that probiotics improved their baby’s health.ConclusionsThese two commonly used probiotics appeared safe and well-accepted by Bangladeshi families.Trial registrationClinicalTrials.gov NCT01899378. Registered July 10, 2013.

Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis

“…The translation from animal studies to clinical application faces many challenges, such as effective dosage and safety in humans. The safety and feasibility of probiotics application in humans have been demonstrated by clinical studies in specific groups, such as in healthy infants, 245 preterm infants, children with intractable diarrhea, 246 and children and adolescents undergoing HCT. 247 However, in patients with predicted severe acute pancreatitis, significant increases in bowel ischemia and mortality were related to probiotic prophylaxis, as reported in the study by Besselink et al 248 Hence, more studies are needed to validate the safety of probiotics and confirm the optimal dosage and the proper time and method of delivery for probiotics in the context of PMO treatment.…”

Role of Lactobacillus reuteri in Human Health and Diseases

“…This organism is most typically found in the proximal digestive tract of the host ( Frese et al, 2013 ). Several studies have assessed the safety of this organism in adults, children, infants, and even in an HIV-infected population ( Wolf et al, 1998 ; Valeur et al, 2004 ; Weizman and Alsheikh, 2006 ; Mangalat et al, 2012 ; Jones et al, 2012a , c ; Hoy-Schulz et al, 2016 ). The results showed that a dose as high as 2.9 × 10 9 colony-forming units (cfu)/day was still well tolerated, safe, and efficacious in humans.…”

Evolutionary changes of an intestinalLactobacillus reuteriduring probiotic manufacture

“…It is estimated that in the USA around 3.9 million people consume prebiotic/ probiotic supplements, probiotics are one of the most consumed dietary supplements (10) and important therapeutic products (8, 11–15). Nevertheless, there are many questions about the efficacy of these products in the medical field (16).…”